Vancomycin-tolerant Streptococcus pneumoniae in Korea by 이경원
  
10.1128/JCM.00558-06. 
2006, 44(10):3524. DOI:J. Clin. Microbiol. 
Wee-Gyo Lee, Yeon-Joon Park and George M. Eliopoulos
Lee, Eui-Chong Kim, Wonkeun Song, Seok Hoon Jeong, 









This article cites 28 articles, 13 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n


















JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2006, p. 3524–3528 Vol. 44, No. 10
0095-1137/06/$08.000 doi:10.1128/JCM.00558-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Vancomycin-Tolerant Streptococcus pneumoniae in Korea
Heungsup Sung,1 Hee Bong Shin,1 Mi-Na Kim,1* Kyungwon Lee,2 Eui-Chong Kim,3 Wonkeun Song,4
Seok Hoon Jeong,5 Wee-Gyo Lee,6 Yeon-Joon Park,7 and George M. Eliopoulos8
Department of Laboratory Medicine, University of Ulsan and Asan Medical Center,1 Department of Laboratory Medicine,
Yonsei University and Severance Hospital,2 Department of Laboratory Medicine, Seoul National University Hospital,3
Department of Laboratory Medicine, Hallym University and Kangnam Sacred Heart Hospital,4 and Department of
Laboratory Medicine, Catholic University and Kangnam St. Mary’s Hospital,7 Seoul, Department of Laboratory Medicine,
Kosin University Gospel Hospital, Busan,5 and Department of Laboratory Medicine, Ajou University Hospital,
Suwon,6 Republic of Korea, and Department of Medicine, Harvard University and
Beth Israel Deaconess Medical Center, Boston, Massachusetts8
Received 15 March 2006/Returned for modification 25 April 2006/Accepted 31 May 2006
A nationwide surveillance study was undertaken to monitor antimicrobial resistance among clinical isolates
of Streptococcus pneumoniae in Korea, with a special focus on vancomycin tolerance. For the 6-month period
from March to August 2002, clinical isolates of S. pneumoniae were collected from 11 university hospitals and
1 reference laboratory. One-hundred eighty-eight isolates were measured for lysis rates after exposure to
vancomycin for 4 h. Two vancomycin-tolerant S. pneumoniae (VTSP) strains, S3 and H8, were isolated from
sputum cultures of two patients, who had stayed in intensive-care units of different hospitals with long-term
antibiotic therapy and were not treated for pneumococcal pneumonia. The penicillin, cefotaxime, and vanco-
mycin MICs for S3 were 8 g/ml, >16 g/ml, and 0.5 g/ml, and those for H8 were 2 g/ml, 2 g/ml, and 0.5
g/ml, respectively. While S3 belonged to serotype 23F and was autolysin defective, H8 belonged to serotype
13F and had intact autolysin. These strains were not clonally related as determined by pulsed-field gel
electrophoresis of chromosomal DNA. In agreement with previous reports, both isolates showed pairing of
TIGR4 vex2 with R6 pep27 and had two identical amino acid substitutions, Q441K in vncS and N25D in vex2.
These findings indicate that two VTSP strains have emerged independently in Korea, suggesting a prevalence
rate of 1.1%. The emergence of VTSP would be a serious threat in Korea, where there are significant rates of
penicillin resistance in S. pneumoniae. Monitoring of the prevalence of VTSP and further investigation of the
clinical relevance of VTSP are warranted.
Streptococcus pneumoniae is the most common cause of bac-
terial meningitis worldwide (23, 28). Pneumococcal meningitis
has a serious mortality rate, ranging from 19% to 26% (22, 23,
32). Over the past decade, the incidence of penicillin resistance
in S. pneumoniae (PRSP) has increased dramatically, and van-
comycin in combination with an extended-spectrum ceph-
alosporin has become the treatment of choice for empirical
therapy of patients with suspected or proven pneumococcal
meningitis in areas where infections caused by PRSP have
been documented (28). In Korea, the frequency of clinical
isolates with resistance to penicillin has risen steadily, from
25% in 1990 to 71.5% in 2000 (9, 11). Moreover, 34% of
clinical isolates from 1989 to 1995 (24) and 47.7% of blood
isolates from 1996 to 2000 were resistant to three or more
classes of antibiotics (10).
Although no vancomycin-resistant strains have been isolated
to date, single therapy with vancomycin was associated with
clinical failure in 4 of 11 cases of meningitis due to relatively
penicillin-resistant pneumococcal strains (31). Vancomycin-
tolerant S. pneumoniae (VTSP) has been described previously
and was subsequently linked to a case of recrudescent menin-
gitis (13). Vancomycin tolerance has been proven to play a role
in therapeutic failure in an experimental rabbit model of pneu-
mococcal meningitis (17), and patients with meningitis caused
by VTSP have been shown to have a poorer survival rate than
patients with meningitis caused by nontolerant strains (21).
Because tolerance is a precursor to the development of resis-
tance, these findings have important implications for the use of
vancomycin for pneumococcal meningitis. The emergence of
VTSP would be a serious threat in countries with significant
rates of PRSP (29).
We conducted a nationwide surveillance study of antimicro-
bial resistance among clinical isolates of S. pneumoniae to
monitor the emergence of vancomycin-tolerant strains.
MATERIALS AND METHODS
Bacterial strains. For the 6-month period from March to August 2002, clinical
isolates of S. pneumoniae were collected from 11 university hospitals located in
four metropolitan cities and four major cities of three provinces and from one
nationwide reference laboratory in Korea. Among these, four hospitals were
located, respectively, in the four boroughs of metropolitan Seoul. As many as 20
strains were collected from each institute, with a rule of one strain per patient.
The strains were stored in brain heart infusion broth with 20% glycerol at70°C.
R6 and Lyt4-4, a LytA-defective laboratory mutant of R6, were used as negative
and positive controls for vancomycin tolerance, respectively (26). All strains were
subcultured on blood agar plates at 37°C under 5% CO2.
Antimicrobial susceptibility. All isolates were tested for susceptibility to pen-
icillin (Sigma-Aldrich, St. Louis, Mo.), cefotaxime (Sigma-Aldrich), meropenem
(AstraZeneca, Cheshire, United Kingdom), and vancomycin (Sigma-Aldrich).
MICs were determined by the broth microdilution method using cation-adjusted
Mueller-Hinton broth (BBL) supplemented with 2.5% lysed horse blood (16).
Interpretive criteria for susceptibility were those indicated in Clinical and Lab-
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oratory Standards Institute (formerly NCCLS) document M100-S16 (3). To
confirm vancomycin tolerance, the minimum bactericidal concentration (MBC)
of vancomycin was measured using the same media and incubation conditions as
those for the MIC tests (15).
Vancomycin-induced lysis rates and definition of tolerance. Vancomycin-in-
duced lysis rates were measured as described previously (6). Briefly, two or three
bacterial colonies from the culture of each isolate were inoculated into 2 ml of
semisynthetic casein hydrolysate medium (12) supplemented with 0.1% yeast
extract (Difco) (c  y medium) and incubated overnight at 37°C under 5% CO2.
When the optical density (OD) of each culture at 620 nm reached 0.20 to 0.30
(5.6  107 to 2.7  108 CFU/ml), vancomycin was added at a concentration
equivalent to 10 times the MIC. Loss of OD was measured hourly for 4 h and
then at 20 h after the addition of vancomycin, and those isolates showing a50%
loss of OD were selected as the candidates for measurement of log kill. Cultures
of candidate isolates were serially diluted in c  y medium before and 4 h after
the addition of vancomycin and were then plated onto blood agar plates. Viable
cells were counted after overnight incubation at 37°C under 5% CO2, and log kill
counts were determined as log10 decreases in viable cell counts. Log kill counts
were performed in duplicate for each candidate. The lysis patterns of R6 and
Lyt4-4 were determined from 20 separate experiments in order to establish the
tolerance limits. After 4 h of exposure to vancomycin, the mean log kill was
4.0 (standard deviation [SD], 0.5) and the mean loss of OD was 56.9%
(SD, 10.4%) for R6, whereas the mean log kill was 1.9 (SD, 0.3) and the
mean loss of OD was 9.1% (SD, 7.1%) for Lyt4-4. The limit that defined
vancomycin tolerance was set at 2 SDs above the means for Lyt4-4 (log kill,
2.5; OD loss, 23.3%).
Sequencing and data analysis. VTSP isolates and R6 were subjected to se-
quencing of vncS, vex2, and pep27. The primers used for PCR and sequencing of
vex2, pep27, and vncS have been described by Rodriguez et al. (21). Sequencing
was performed using the ABI PRISM dye terminator cycle sequencing ready
reaction kit and AmpliTaq DNA polymerase (Perkin-Elmer Applied Biosys-
tems) on a model 373 automated DNA sequencer (Perkin-Elmer, Foster City,
CA). The deduced amino acid sequences were aligned with those of reference
isolates TIGR4 (GenBank accession no. NC 003028) and R6 and with those of
vancomycin-tolerant strains I95, A378, and A43, published elsewhere (6).
Autolysin activity. For vancomycin-tolerant isolates, active autolysin was de-
tected by visible clearing of the suspensions of their cultures in 2% sodium
deoxycholate and by the abilities of their cellular extracts to reconstitute the
penicillin-induced lysis of the autolysin-defective isolate Lyt4-4 (27).
Serotyping and PFGE. Vancomycin-tolerant isolates were serotyped by the
capsular quellung method with commercial antisera (Statens Seruminstitut, Co-
penhagen, Denmark) as recommended by the manufacturer. The relatedness of
vancomycin-tolerant isolates was determined by pulsed-field gel electrophoresis
(PFGE) of chromosomal DNA restricted with SmaI and ApaI (7).
RESULTS
Antimicrobial susceptibility. A total of 188 isolates were
collected: 121 from lower respiratory tract specimens, 26 from
blood cultures, 12 from middle ear aspirates, 2 from cerebro-
spinal fluid (CSF), and 27 from other sites. Forty-three
(22.9%) isolates were from patients 15 years old. Among all
isolates, 29.3%, 62.8%, 42.6%, and 100% were susceptible to
penicillin, cefotaxime, meropenem, and vancomycin, respec-
tively. The penicillin MICs at which 50% and 90% of the
isolates were inhibited were 2 g/ml and 4 g/ml, respectively.
Penicillin-susceptible isolates were susceptible to all four
drugs. But of the 100 penicillin-resistant isolates, 70 (70%),
including 2 CSF isolates, were susceptible to neither cefo-
taxime nor meropenem. All of the isolates had vancomycin
MICs ranging from 0.12 g/ml to 1 g/ml.
Vancomycin tolerance. The mean loss of OD of 188 isolates
at 4 h was 56.6% (SD, 12.3%). Twenty isolates showing
50% losses of OD were counted for viable cells to confirm
the vancomycin-induced lysis rate. Most of the 20 clinical iso-
lates showed substantial losses of OD, and viable cell counts
similar to those of R6. Only two isolates, S3 and H8, were
consistent with the definition of vancomycin tolerance: the
losses of OD for S3 and H8 were 0.3% and 19.2%, respectively,
and the mean log kills were 1.3 and 1.5, respectively (Fig. 1).
The MBC-to-MIC ratios of vancomycin were 64 for both
(Fig. 2).
Characterization of vancomycin-tolerant strains. S3 was iso-
lated from a sputum culture of a 91-year-old man admitted to
the medical intensive-care unit of a tertiary-care hospital in
Seoul, and H8 was isolated from a sputum culture of a 78-year-
old man admitted to the medical intensive-care unit of a sec-
ondary-care hospital in Seoul. In both cases, S. pneumoniae
was not the target of therapy at the time. Both patients had
been repeatedly treated with various antibiotics, including
cefotaxime and vancomycin, for prolonged periods prior to the
isolation of S. pneumoniae. The MICs of penicillin, cefotaxime,
meropenem, and vancomycin for S3 were 8 g/ml, 16 g/ml,
1 g/ml, and 0.5 g/ml, respectively, whereas the correspond-
ing MICs for H8 were 2 g/ml, 2 g/ml, 0.5 g/ml, and 0.5
g/ml, respectively. The serotypes of S3 and H8 were 23F and
13F, respectively. PFGE analysis showed that they were not
clonally related.
Upon exposure to deoxycholate, H8 underwent rapid lysis,
like R6, whereas S3 did not, like Lyt4-4. Moreover, lysates of
H8, like those of R6, reconstituted the lysis activity of the
autolysin-deficient strain Lyt4-4, whereas lysates of S3 did not,
indicating that S3 was autolysin defective (Fig. 3).
The sequence of R6 was consistent with the published se-
quence in GenBank (accession no. AE008431). Compared to
the sequences of reference strains TIGR4 and R6, the se-
quences of S3 and H8 have identical single-amino-acid substi-
tutions—a glutamine-to-lysine substitution at position 441 of
the vncS gene and an asparagine-to-aspartic acid substitution
at position 25 of the vex2 gene—that differentiate them from
the published sequences of vancomycin-tolerant strains I95,
A378, and A43 (6). While the vex2 alleles of S3 and H8 showed
the TIGR4 type, characterized by arginine at position 102 and
asparagine at position 111, their pep27 alleles showed the R6
type, harboring a glycine-to-aspartic acid substitution at posi-
FIG. 1. Mean percent loss of OD and log kill after addition of
vancomycin (at a concentration equivalent to 10 times the MIC) for 20
candidate clinical isolates of pneumococci. The values for R6 and
Lyt4-4 are also shown. Isolates S3 and H8 showed rates of killing and
lysis similar to those of the autolysin-defective mutant Lyt4-4. Dashed
lines indicate the limits of tolerance.
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tion 12 and an alanine-to-tyrosine substitution at position 16
(Fig. 4).
DISCUSSION
Of our 188 clinical isolates, 2 (1.1%) were tolerant van-
comycin. Because Korea is one of the countries that suffer
from the highest incidences of PRSP infection (25), this
prevalence of VTSP could pose serious concerns. However,
this prevalence may have been overestimated, because
pneumococcal isolates were mostly collected from large uni-
versity hospitals, and about one third of the isolates came
from tertiary-care hospitals in metropolitan Seoul. By 2003,
six clinical VTSP isolates had been reported sporadically (2,
6, 8, 13). Surveillance studies from 2001 to 2005 have re-
ported VTSP prevalences ranging from 0% to 2.6% in Swe-
den, Spain, Hong Kong, France, and the United States (1, 2,
4–6, 19). In 2004, Rodriguez et al. (21) reported VTSP
prevalences of 8.1% among the 457 nasopharyngeal isolates
collected from healthy newborns between 1999 and 2002,
and 10.6% and 3.3% for 113 blood and CSF isolates and 215
nasopharyngeal isolates of healthy infants, respectively, re-
trieved from the archival collection of 1998. However, they
modified the criteria for defining tolerance from 2 SDs
above the mean log kill of Lyt4-4 (6) to 2 SDs below that
of R6 (21). Differences in VTSP prevalence may depend on
the methods used to define vancomycin tolerance, as well as
on the patient population and its geographic distribution.
To estimate the prevalence of VTSP reliably, the method
and criteria used to define vancomycin tolerance must be
standardized.
To our knowledge, S3 was the first clinical isolate of autol-
ysin-defective VTSP. Although the exact mechanism underly-
ing vancomycin tolerance is still unclear, it is apparently re-
lated to a defect in autolysis (6, 17). The lack of autolysin alone
can explain vancomycin tolerance, as exemplified by the orig-
inal lytA defective mutant (27). Even though two VTSP isolates
emerged from two patients independently and were not
clonally related, they shared several genetic characteristics. In
this study, we detected novel single-amino-acid substitutions,
Q441K of vncS and N25D of vex2, in both S3 and H8. VncS-
VncR, Vex, and Pep27 are involved in the signal transduction
cascades to activate autolysin (LytA). VncS is a histidine kinase
that acts as the sensor of a two-component regulatory system
sensing the accumulation of Pep27 and subsequently leading to
activation of LytA. Vex is the transporter protein inducing the
secretion of Pep27 to the extracellular compartment (14, 17,
18). The V440A substitution in vncS has been proposed to
cause tolerance in early VTSP isolates (6). A functional defect
in any part of these signal transduction cascades hypothetically
results in tolerance (18). However, loss of VncS function alone
has not been proven to cause vancomycin tolerance, and the
frequencies of V440A were found to be similar in tolerant and
nontolerant isolates (20, 21). We did not investigate the effect
of the novel amino acid substitutions found in this study. Both
isolates S3 and H8 showed a combination of a TIGR4 vex2
allele and an R6 pep27 allele. This finding is consistent with the
report of Rodriguez et al. that vancomycin-tolerant isolates
show a significant tendency to have this combination (21). As
a summary, the vancomycin tolerance found in this study may
possibly be attributed to any of three kinds of mechanisms: a
defect in autolysis in one isolate, a functional defect in the
VncS-VncR system, and the combination of TIGR4 vex2 and
R6 pep27 alleles.
Two vancomycin-tolerant strains were highly resistant
to penicillin and cefotaxime. Among 188 clinical isolates,
the prevalences of penicillin-intermediate and -resistant S.
pneumoniae were 17.6% and 53.2%, respectively, findings
similar to those of previous reports (9, 10, 25). Published
cases of VTSP were all penicillin intermediate or penicillin
resistant (2, 6, 8, 13). These findings are consistent with the
presumption that selective pressure by antibiotics acceler-
ates the development of tolerance and resistance (21). Due
to the very high rate of -lactam resistance, a high risk of
emergence of VTSP may be anticipated. VTSP emergence
could seriously limit the therapeutic options for S. pneu-
moniae infection in Korea.
FIG. 2. MBCs of vancomycin for S3, H8, and control strains ATCC
49619, R6, and Lyt4-4. Gray circles, no growth detected on 1-ml
cultures.
FIG. 3. Functional assay of autolytic activity of vancomycin-toler-
ant strains by reconstitution of penicillin-induced lysis of Lyt4-4. Crude
cellular extracts of S3, H8, R6, or Lyt4-4 were added to cultures of
Lyt4-4 together with 0.1 g/ml penicillin, and then the OD at 620 nm
was measured at 0 h, 8 h, and 24 h.
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Because the patients from whom S3 and H8 was isolated
were not being treated for pneumococcal pneumonia, the clin-
ical impact of VTSP could not be assessed in this study. Except
for a case of pneumococcal meningitis, the clinical relevance of
vancomycin tolerance has not been investigated yet (12, 21). In
the previous report investigating lysis-defective strains, a defect
in penicillin-induced lysis was shown to affect the course of
meningitis adversely, despite appropriate -lactam treatment,
but not that of bacteremia (30). To establish the clinical rele-
vance of VTSP, a much larger study involving more cases of
VTSP infection would be required.
In conclusion, VTSP, with a prevalence of 1.1% in this study,
has emerged from PRSP in Korea. Given the high incidence of
penicillin resistance, the emergence of VTSP is more likely and
furthermore would have a greater impact on therapeutic op-
tions for pneumococcal meningitis in Korea. Further monitor-
ing of the prevalence, and further investigation of the clinical
relevance, of VTSP is warranted.
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